Heart Transplant Failure and Rejection Clinical Trial
Official title:
Bioelectrical Impedance Spectroscopy in Heart Transplantation: Tracking Post-Transplant Changes in Body Composition and Correlation With Conventional Preoperative Risk Assessment Modalities
Patients with marginal physiologic reserve, severe frailty, and/or malnutrition may be regarded as unsuitable candidates for advanced cardiac replacement therapies. However, little data exist on precisely which measures are predictive of subsequent adverse events. Assessment of nutritional status and frailty is still largely predicated on crude and obsolete parameters, such as baseline serum albumin level or body mass index (BMI). In this prospective cohort study the investigators will evaluate the use of bio-electrical impedance spectroscopy (BIS) as a measure of body composition and assess the associations with surgical outcomes.
This is a prospective cohort study, with study visits at Enrollment and subsequently at ≤10 days , 1 month (+/- 7 days), 3 months (+/- 7 days) , 6 months (+/- 14 days) , and 12 months (+/- 14 days) after heart transplant surgery. BIS measurements will be performed on patients both in the pretransplant and post-transplant periods except when contraindicated in the pretransplant setting concerning patients with advanced heart failure. Because the use of BIS is contraindicated in the setting of permanent pacemaker and/or internal cardiac defibrillator (ICD) devices, BIS assessment cannot be performed in the pretransplant setting for patients with advanced heart failure as the majority of these patients already have these devices in place. However, at the time of cardiac transplantation, these devices will be removed from those patients with advanced heart failure and the BIS measurements will then be performed shortly after transplantation, and then serially during the post-transplant period at various time intervals for one year in order to track changes in body composition. These measurements will be compared to traditional measurements performed at the time of preoperative evaluation by the nutritional and dietitian support team. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03102125 -
Allograft Dysfunction in Heart Transplant
|
Phase 4 | |
Active, not recruiting |
NCT04380311 -
Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant
|
N/A | |
Completed |
NCT02109575 -
Quantitative Detection of Circulating Donor-Specific DNA in Organ Transplant Recipients (DTRT-Multi-Center Study)
|
||
Not yet recruiting |
NCT06414603 -
A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy
|
N/A | |
Completed |
NCT04610320 -
Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation
|
Phase 1 | |
Active, not recruiting |
NCT03386539 -
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
|
Phase 3 | |
Withdrawn |
NCT05081739 -
Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation
|
N/A | |
Recruiting |
NCT03499197 -
Heart TIMING - Heart Transplantation IMagING
|
||
Recruiting |
NCT03538509 -
Percutaneous Coronary Intervention in Patients witH OrthotoPic hEart Transplantation: the PCI-HOPE a Multicenter Study.
|
||
Recruiting |
NCT03050892 -
Impact of Donor and Recipient ST2 / IL-33 Pathway After Heart Transplantation
|
N/A | |
Recruiting |
NCT05994274 -
A Clinical Study of Association Between Postoperative Dyslipidemia and Organ Rejection in Transplant Patients
|
||
Active, not recruiting |
NCT03575910 -
HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection
|
||
Not yet recruiting |
NCT06453148 -
Brazilian Clinical Registry of Heart Transplantation
|
||
Withdrawn |
NCT04088903 -
Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation
|
Phase 1 |